Evolus, Inc. (EOLS) Research

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Market snapshot

Symbol
EOLS
Price
$6.63
Day change
-1.63%
Market cap
$436.6M
P/E ratio
-9.95x
52-week range
3.86-10.2
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months
Analyst price target
$15.00

Peer companies

  • Autolus Therapeutics plc (AUTL)
  • CeriBell, Inc. (CBLL)
  • Enhabit, Inc. (EHAB)
  • OrthoPediatrics Corp. (KIDS)
  • Kamada Ltd. (KMDA)
  • Neurogene Inc. (NGNE)
  • Quantum-Si incorporated (QSI)
  • Solid Biosciences Inc. (SLDB)

Recent insider activity

  • Avelar Rui — S-Sale (3119 shares) on 2026-03-20
  • MOATAZEDI DAVID — S-Sale (13669 shares) on 2026-03-20
  • MOATAZEDI DAVID — M-Exempt (67489 shares) on 2026-03-16
  • MOATAZEDI DAVID — S-Sale (116720 shares) on 2026-03-17
  • MOATAZEDI DAVID — M-Exempt (67489 shares) on 2026-03-16

Open Evolus, Inc. (EOLS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.